Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.
With four new entrants readying to be prescribed in the next four years, the market for diabetic nephropathy is looking more buoyant than ever. However, competition from GLP-1 agonists and eventually from generics could put a dampener on proceedings.
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.
The active pharmaceuticals ingredients segment in India appears to be coming into its own, alongside signs of a revival in the overall sales growth of Indian generic firms in FY2019, a study by an Indian investment banking and consulting services firm has indicated.
Metastatic castration-sensitive prostate cancer could see a marketing race following positive top-line clinical data for Janssen’s apalutamide in the Phase III TITAN study.
The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.
UroGen's reverse thermal gel formulation of mitomycin produced a high rate of complete responses in patients with urothelial cancer; developing a commercialization strategy for the product will benefit from the experience of the company's new CEO.
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
The relative absence of blockbuster M&A within medtech in 2018, compared with recent years, does not mean that consolidation of the industry – and of providers and payers – will not continue apace in 2019 and beyond. In fact, it is written – if not in the stars then possibly in digital coding – that there will be fewer and bigger entities at the top end of the ecosystem of medtech stakeholders. And rising demand will be met more and more by digital tools and functionalities.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.